Januvia 25mg (Sitagliptin)

Introduction

Januvia is the name of the brand to refer to Sitagliptin, an innovative oral anti-diabetic drug that belongs to the class of Dipeptidyl Peptidase-4 (DPP-4) inhibitors. Januvia tablets with a dose of 25 mg are typically prescribed for the treatment of Type 2 Diabetes Mellitus (T2DM), either as a stand-alone medication or when combined with other medications to treat antidiabetic disorders.

Pharmacology

• Mechanism of Action: Sitagliptin inhibits in a selective manner the enzyme DPP-4that reduces hormones that are incretin-like, such as GLP-1 (glucagon-like propeptide-1) as well as GIP (glucose-dependent insulinotropic polypeptide). Inhibiting DPP-4 raises the level of active incretins, and these:
  • Increase insulin production in a glucose-dependent way.
  • Reduce the secretion of glucagon from the pancreas.
• This double action can help decrease both postprandial as well as fasting blood glucose levels, but without creating significant hypoglycemia.

Indications

Januvia 25 mg is recommended to treat:

• Therapy to enhance the control of glycemic levels in people suffering from Type 2 diabetes mellitus.
• It can be used in individual therapy for patients when metformin is not recommended or well-tolerated.
• In conjunction with other oral anti-diabetic drugs or insulin when glucose control is needed.

Dosage and Administration

• Recommended Dose: In adults, the standard dose for adults is 100 mg each day. In reality, 25 mg tablets can be used to make a dosage adjustment specifically for patients with kidney impairment.
• The dosage of 25 mg is especially recommended for patients suffering from severe to moderate kidney impairment (eGFR < 50 mL/min/1.73 m²).
• The dosage can be taken either with or without food.
• Tablets are best swallowed whole, along with a glass of water.

Pharmacokinetics

• Sitagliptin is absorbed quickly following the administration of sitagliptin by mouth.
• The peak plasma concentration is reached within a period of 1 to 4 hours.
• The elimination half-life of approximately 12.4 hours.
• The majority of the time, it is excreted unchanged in the urine.
• Adjustments to doses are necessary in patients who have impairment in kidney function.

Contraindications

• Hypersensitivity to sitagliptin or other component of the formulation.
• Type 1 diabetes, also known as diabetic ketoacidosis (Januvia isn’t effective for those conditions).

Side Effects

Common Side Effects:

• Nasopharyngitis (common cold symptoms).
• Headache.
• Upper respiratory tract infections.
• Gastrointestinal symptoms (nausea, diarrhea).

Serious Side Effects (Rare):

• Pancreatitis (symptoms include severe abdominal pain).
• Hypersensitivity reactions (rash, swelling, anaphylaxis).
• Severe joint pain.
• Hypoglycemia (especially when used with insulin or sulfonylureas).

Precautions

• Check renal function frequently, and dose adjustments are essential when there is a problem with renal function.
• Be cautious for patients who have a previous history of pancreatitis.
• Patients are advised to inform the doctor of any pancreatitis symptoms promptly.
• Check for any indications of allergy reactions.
• Beware when taking other drugs that can result in hypoglycemia.

Use During Pregnancy and Lactation

• The data available is not extensive on the usage of sitagliptin during pregnancy; use only if it is clearly required.
• There is no information on whether sitagliptin excreted by humans, is absorbed into milk. It is recommended to be cautious for breastfeeding mothers when sitagliptin is administered.

Drug Interactions

• Higher risk of hypoglycemia using insulin and insulin secretagogues (e.g. or sulfonylureas).
• There are no significant interactions with the majority of commonly used medications.
• Make adjustments to doses of the other anti-diabetic drugs as needed.

Patient Counseling

• Take Januvia as prescribed; do not skip doses.
• Keep a healthy and balanced diet. Also, do a daily workout.
• Inform us of any pancreatitis symptoms or reactions to an allergic trigger immediately.
• Monitor blood glucose levels regularly.
• Your healthcare professional should be aware of any medications you’re taking.

Storage

• Keep at the room temperatures (20-25°C or 68-77°F).
• Avoid extreme heat and humidity.
• Be sure to keep away from youngsters.

Summary

Januvia 25 mg (Sitagliptin) is a potent DPP-4 inhibitor for managing Type 2 Diabetes Mellitus. It functions by increasing the levels of incretin, which results in improved secretion of insulin and reducing the release of glucagon in a glucose-dependent way. The safety profile of the drug and the daily dose make it a suitable choice for a lot of patients, particularly those who require dose adjustments.